Lazard Asset Management’s Usana Health Sciences USNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.08M | Buy |
97,311
+24,916
| +34% | +$468K | ﹤0.01% | 967 |
|
|
2026
Q1 | $1.26M | Buy |
+72,395
| New | +$1.44M | ﹤0.01% | 1090 |
|
|
2025
Q3 | – | Sell |
-23,201
| Closed | -$708K | – | 2337 |
|
|
2025
Q2 | $708K | Buy |
23,201
+13,128
| +130% | +$373K | ﹤0.01% | 1404 |
|
|
2025
Q1 | $271K | Buy |
10,073
+2,862
| +40% | +$90.6K | ﹤0.01% | 1563 |
|
|
2024
Q4 | $258K | Buy |
7,211
+7,182
| +24,766% | +$269K | ﹤0.01% | 1541 |
|
|
2024
Q3 | $1K | Sell |
29
-842
| -97% | -$34.6K | ﹤0.01% | 2217 |
|
|
2024
Q2 | $39K | Hold |
871
| – | – | ﹤0.01% | 1967 |
|
|
2024
Q1 | $42K | Hold |
871
| – | – | ﹤0.01% | 1753 |
|
|
2023
Q4 | $46K | Buy |
+871
| New | +$44.1K | ﹤0.01% | 1907 |
|
|
2023
Q3 | – | Sell |
-753
| Closed | -$47K | – | 2484 |
|
|
2023
Q2 | $47K | Buy |
+753
| New | +$48K | ﹤0.01% | 1857 |
|
|
2022
Q3 | – | Sell |
-225
| Closed | -$16K | – | 2565 |
|
|
2022
Q2 | $16K | Buy |
+225
| New | +$16.8K | ﹤0.01% | 2165 |
|
|
2022
Q1 | – | Sell |
-658
| Closed | -$66K | – | 2539 |
|
|
2021
Q4 | $66K | Buy |
658
+97
| +17% | +$9.68K | ﹤0.01% | 1624 |
|
|
2021
Q3 | $51K | Sell |
561
-19,737
| -97% | -$1.9M | ﹤0.01% | 1680 |
|
|
2021
Q2 | $2.08M | Buy |
20,298
+8,744
| +76% | +$878K | ﹤0.01% | 846 |
|
|
2021
Q1 | $1.13M | Sell |
11,554
-54,067
| -82% | -$4.92M | ﹤0.01% | 886 |
|
|
2020
Q4 | $5.06M | Buy |
65,621
+11,085
| +20% | +$857K | 0.01% | 655 |
|
|
2020
Q3 | $4.02M | Buy |
54,536
+20,393
| +60% | +$1.64M | 0.01% | 635 |
|
|
2020
Q2 | $2.51M | Buy |
+34,143
| New | +$2.68M | ﹤0.01% | 652 |
|
|
2020
Q1 | – | Sell |
-18
| Closed | -$1K | – | 1765 |
|
|
2019
Q4 | $1K | Sell |
18
-17,246
| -100% | -$1.27M | ﹤0.01% | 1500 |
|
|
2019
Q3 | $1.18M | Sell |
17,264
-28,925
| -63% | -$1.94M | ﹤0.01% | 731 |
|
|
2019
Q2 | $3.67M | Sell |
46,189
-3,070
| -6% | -$243K | 0.01% | 655 |
|
|
2019
Q1 | $4.13M | Sell |
49,259
-58,227
| -54% | -$6.08M | 0.01% | 624 |
|
|
2018
Q4 | $12.7M | Sell |
107,486
-3,681
| -3% | -$426K | 0.02% | 353 |
|
|
2018
Q3 | $13.4M | Buy |
111,167
+12,425
| +13% | +$1.54M | 0.02% | 370 |
|
|
2018
Q2 | $11.4M | Buy |
98,742
+98,469
| +36,069% | +$10.8M | 0.02% | 410 |
|
|
2018
Q1 | $23K | Buy |
+273
| New | +$21.1K | ﹤0.01% | 949 |
|
|
2016
Q2 | – | Sell |
-17,200
| Closed | -$1.04M | – | 1106 |
|
|
2016
Q1 | $1.04M | Buy |
+17,200
| New | +$1.01M | ﹤0.01% | 671 |
|
Other funds holding USNA
NCM
Lazard Asset Management's USNA Position: Q2 2026 in Review
Lazard Asset Management increased its Usana Health Sciences (USNA) stake by 34% in Q2 2026, buying an estimated $468K and bringing the position to 97,311 shares worth $2.08M. The position accounts for ﹤0.01% of the portfolio, ranked #967.
Lazard Asset Management first reported a position in USNA in Q1 2016 and has held it in 27 quarters since. The position peaked at $13.4M in Q3 2018. 138 funds tracked by Wall St. Rank hold USNA as of Q2 2026.
- Lazard Asset Management held 97,311 shares of Usana Health Sciences worth $2.08M as of Q2 2026.
- Lazard Asset Management bought 24,916 Usana Health Sciences shares in Q2 2026, an estimated $468K.
- Usana Health Sciences made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #967 holding.
- Lazard Asset Management first reported a position in Usana Health Sciences in Q1 2016 and has held it in 27 quarters since.
- Lazard Asset Management's Usana Health Sciences position peaked at $13.4M in Q3 2018.
- 138 funds tracked by Wall St. Rank held Usana Health Sciences as of Q2 2026.
Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.